A unique platform that integrates functional measurements from brain organoids with advanced AI analysis to estimate the efficacy of drugs for neurological and psychiatric disorders.
In the realm of neurological and psychiatric disorders, traditional drug development methods are failing us. Animal models, particularly mice, often do not predict human outcomes accurately.
Of drugs developed on mice fail in human clinical trials
New drugs
FDA-approved for neurological and psychiatric disorders in 20 years
Success rate in translating preclinical studies to clinical trials
Welcome to the future of neurological and psychiatric drug development –
where human-derived mini-brains meet cutting-edge AI.
Our innovative platform combines patient-derived brain organoids, advanced AI technology, and unparalleled functional readouts to break the deadlock
in drug discovery.
Miniature 3D replicas of human brains grown from patient cells, providing a more accurate model than traditional animal testing.
EEG-like measurements and other advanced techniques provide unprecedented insights into drug efficacy and brain function.
Unparalleled drug and compound efficacy prediction based on electrophysiological readouts combined with advanced AI analysis.
This video showcases the electrophysiological activity of brain organoids from autism spectrum disorder patients and healthy volunteers. Our system, combined with AI analysis, can identify functional abnormalities compared to the control electrophysiological activity.
This data presents a visualization of brain organoids through three-dimensional reconstruction. It enables the detection of morphological and size abnormalities in patients with autism spectrum disorders compared to the control brain organoids.
Here, we present a significant improvement in the functional readout of autism spectrum disorder brain organoids using an FDA-approved compound from a repurposed drug. Our data demonstrates the ability of this system to align with clinical results and test the efficacy of different drugs and compounds on patients.
Advancing drug development: from concept to market
Starting with low-functioning Autism disorders and expanding to other pathologies
Our groundbreaking work in autism, conducted in collaboration with Hadassah University Medical Center, showcases the power of our platform to revolutionize neurological research and drug development.
In our studies, we successfully distinguished between organoids derived from individuals with autism and those from neurotypical individuals. We also tested on additional pathologies such as epilepsy.
Our research is based on clinical samples from volunteers on the autism and neurodevelopmental spectrum. Contact us to check your eligibility for participation.
Itay&Beyond revolutionizes neuropsychiatric drug discovery by combining brain organoids, dynamic brain function measurement, and AI analysis. Our platform predicts drug efficacy early in development, reducing failures in human trials and accelerating drug discovery. This approach offers new hope to millions affected by neurological and psychiatric disorders, providing an efficient path to developing treatments for a wide range of conditions.
Itay&Beyond was founded by Mr. Shmulik Bezalel and inspired by his son Itay, who has Autism Spectrum Disorder (ASD). Recognizing the limited therapeutic options for neuropsychiatric disorders, Mr. Bezalel joined forces with Mr. Boaz Goldman and Dr. Nisim Perets to establish the company.
Led by pioneers in neuroscience and biotech, Itay&Beyond combines cutting-edge expertise with a passion for transforming lives.
Co-Founder and CEO
Distinguished neuroscientist with high-impact publications and innovative research in drug development.
Co-Founder and Investor
Visionary entrepreneur inspired by personal experience to revolutionize autism research.
Co-Founder and Investor
Seasoned entrepreneur and investor with a track record of nurturing groundbreaking technologies.
Co-Founder and CEO
Distinguished neuroscientist with high-impact publications and innovative research in drug development.
Co-Founder and Investor
Visionary entrepreneur inspired by personal experience to revolutionize autism research.
Co-Founder and Investor
Seasoned entrepreneur and investor with a track record of nurturing groundbreaking technologies.
Former VP Innovation at Global GSK
Head of Innovation Center at Lonza Israel
CEO Takeda Israel
Former CEO of Ministry of Foreign Affairs
Led the $110M investment in Pfizer
Head of Children’s Neurological Dept., Hadassah
Ready to revolutionize your approach to drug discovery? Collaborate with us and harness cutting-edge technology to achieve more efficient, accurate, and ethical research.